Welcome to our dedicated page for LakeShore Biopharma Co. news (Ticker: LSBCF), a resource for investors and traders seeking the latest updates and insights on LakeShore Biopharma Co. stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect LakeShore Biopharma Co.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of LakeShore Biopharma Co.'s position in the market.
LakeShore Biopharma (Nasdaq:LSB) announced that effective September 22, 2025 its ordinary shares and warrants were suspended from trading on Nasdaq and are expected to begin trading on the OTC Pink Open Market under symbols LSBCF (shares) and LSBWF (warrants).
The Nasdaq action follows a delisting determination dated September 11, 2025 due to non-compliance with the minimum bid price rule and ineligibility for a compliance period because of a prior reverse stock split. The company said the transition does not change business operations and that it remains a reporting company with the SEC.
LakeShore Biopharma (OTCPK: LSBCF / LSBWF) entered into a definitive Agreement and Plan of Merger with Oceanpine Skyline Inc. and its Merger Sub to become a privately held company in a transaction implying an equity value of approximately US$37 million. At the effective time each outstanding ordinary share (other than excluded/dissenting shares) will be cancelled for US$0.90 per share in cash. The consideration reflects a ~15.4% premium to the closing price on August 15, 2025. The deal is expected to close in Q1 2026, is subject to customary closing conditions and a shareholder vote requiring at least a two-thirds approval, and would remove the company’s shares from the OTC Pink Open Market.
The transaction is funded by an equity commitment and a rollover by certain shareholders who represent ~53.35% of voting rights.
LakeShore Biopharma (Nasdaq: LSB) announced its transition from Nasdaq to the OTC Pink Open Market effective September 22, 2025. The company's ordinary shares and warrants will trade under the new symbols "LSBCF" and "LSBWF" respectively.
The delisting from Nasdaq follows a determination letter received on September 11, 2025, citing non-compliance with the minimum bid price requirement and ineligibility for a compliance period due to a previous reverse stock split. Despite the market transition, LakeShore Biopharma maintains its SEC reporting status and business operations remain unchanged.
FAQ
What is the current stock price of LakeShore Biopharma Co. (LSBCF)?
